MedTrace Logo

A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine

NCT00833963 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2019-05-16

No results posted yet for this study

Summary

The MotHER Pregnancy Registry is a United States (U.S.)-based, prospective, observational cohort study in women with breast cancer who have been or are being treated with a trastuzumab (herceptin)-containing regimen with or without pertuzumab (perjeta) or ado-trastuzumab emtansine (kadcyla) during pregnancy or within 7 months prior to conception (regardless of cancer stage at the time of trastuzumab, pertuzumab, or ado-trastuzumab emtansine exposure).

Conditions

Interventions

DRUG

Trastuzumab

Participants will receive trastuzumab as determined by their treating physicians' standards of care.

DRUG

Pertuzumab

Participants will receive pertuzumab as determined by their treating physicians' standards of care.

DRUG

Ado-Trastuzumab Emtansine

Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Vikki Brown, M.D. · Syneos Health

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-14
Primary Completion
2017-04-13
Completion
2017-04-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00833963 on ClinicalTrials.gov